Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. (PCSA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PCSA · as of Dec 31, 2023
Ownership Breakdown
18
Institutional Holders
▼ 2 vs Q3
$376,475
Total Inst. Value
▲ $26,655 vs Q3
2.27M
Shares Outstanding
freeFloat 90.05%
1.13M
13F Shares Held
▼ 255,338 vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PCSA largest shareholders · institutional ownership
Q4 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CITADEL ADVISORS LLC pharmaceutical preparations | 315.4K | 1.17% | 1.17% | $105.54M | Feb 14, 2024 | ▲ 149.2K |
VANGUARD GROUP INC pharmaceutical preparations | 234.7K | 86.90% | 86.90% | $78.52M | Mar 11, 2024 | ▼ 109.8K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 122.0K | 45.19% | 45.19% | $40.83M | Feb 13, 2024 | ▼ 30.6K |
UBS GROUP AG pharmaceutical preparations | 80.0K | 29.63% | 29.63% | $26.81M | Feb 9, 2024 | ▲ 79.3K |
SPINNAKER TRUST pharmaceutical preparations | 76.9K | 28.47% | 28.47% | $25.72M | Feb 2, 2024 | NEW |
COASTAL BRIDGE ADVISORS, LLC pharmaceutical preparations | 65.0K | 24.06% | 24.06% | $21.73M | Feb 15, 2024 | ▲ 12.5K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 58.2K | 21.55% | 21.55% | $19.00M | Feb 13, 2024 | ▲ 4.3K |
ROYAL BANK OF CANADA pharmaceutical preparations | 46.3K | 17.15% | 17.15% | $15.00M | Feb 14, 2024 | ▼ 76 |
STATE STREET CORP pharmaceutical preparations | 42.8K | 15.84% | 15.84% | $14.32M | Feb 14, 2024 | — held |
NORTHERN TRUST CORP pharmaceutical preparations | 28.1K | 10.42% | 10.42% | $9.41M | Feb 13, 2024 | ▲ 12.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2023 vs prior quarter
Q4 2023
6
Increased
+258.0K shares4
New Positions
first time holders5
Decreased
−157.0K shares6
Sold Out
fully exitedNet shares change (top 50)
+101.0K
+258.0K / −157.0K
Net new holders
-1
4 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PCSA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Young David Pres. Research & Development | May 29, 2026 | Purchase | 1,786 | $2.57 | $4.6K | 17.1K | Form 4 ↗ |
SKIBSTED RUSSELL Chief Financial Officer | May 29, 2026 | Purchase | 2,292 | $2.57 | $5.9K | 10.8K | Form 4 ↗ |
Ng George K Chief Executive Officer | May 29, 2026 | Purchase | 2,129 | $2.57 | $5.5K | 10.0K | Form 4 ↗ |
Lin Patrick Chief Business - Strategy Off | May 29, 2026 | Purchase | 1,582 | $2.57 | $4.1K | 9.2K | Form 4 ↗ |
Guy Wendy Chief Administrative Officer | May 29, 2026 | Purchase | 1,829 | $2.57 | $4.7K | 9.8K | Form 4 ↗ |
Ng George K Chief Executive Officer | May 15, 2026 | Purchase | 1,843 | $2.97 | $5.5K | 7.8K | Form 4 ↗ |
Young David Pres. Research & Development | May 15, 2026 | Purchase | 1,545 | $2.97 | $4.6K | 15.3K | Form 4 ↗ |
Lin Patrick Chief Business - Strategy Off | May 15, 2026 | Purchase | 1,369 | $2.97 | $4.1K | 7.6K | Form 4 ↗ |
Guy Wendy Chief Administrative Officer | May 15, 2026 | Purchase | 1,583 | $2.97 | $4.7K | 8.0K | Form 4 ↗ |
SKIBSTED RUSSELL Chief Financial Officer | May 15, 2026 | Purchase | 1,984 | $2.97 | $5.9K | 8.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Processa Pharmaceuticals, Inc. (PCSA) is primarily owned by institutional investors, who hold approximately 49.9% of total shares outstanding. Company insiders own approximately 9.95%, while retail and public investors account for the remaining 40.15%.
The largest institutional shareholder of Processa Pharmaceuticals, Inc. is CITADEL ADVISORS LLC, holding approximately 315,410 shares — equal to 1.17% of outstanding shares — as of December 31, 2023.
A total of 18 institutional investors currently hold PCSA stock, with a combined institutional value of approximately $376,475 as of the most recent 13F filing period.
Frequently asked questions
PCSA ownershipProcessa Pharmaceuticals, Inc. (PCSA) is primarily owned by institutional investors, who hold approximately 49.9% of shares. The largest shareholder is CITADEL ADVISORS LLC with a 1.17% stake. Company insiders hold 9.95%. Data sourced from SEC Form 13F as of December 31, 2023.